Trials / Conditions / Relapsed/Refractory Follicular Lymphoma

Relapsed/Refractory Follicular Lymphoma

12 registered clinical trials studyying Relapsed/Refractory Follicular Lymphoma — 8 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Re NCT07418190	The First Affiliated Hospital with Nanjing Medical University	Phase 2
Not Yet Recruiting	IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed NCT07355283	ImmuneOnco Biopharmaceuticals (Shanghai) Inc.	Phase 3
Recruiting	Study to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma (FL) NCT07278921	Andrés José Maria Ferreri	—
Not Yet Recruiting	A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/ NCT07031700	Tianjin Medical University Cancer Institute and Hospital	Phase 2
Recruiting	A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combine NCT06149286	Regeneron Pharmaceuticals	Phase 3
Active Not Recruiting	Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Foll NCT05371093	Kite, A Gilead Company	Phase 3
Completed	Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed or Refractory Foll NCT05338879	Regeneron Pharmaceuticals	—
Recruiting	A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refrac NCT05100862	BeiGene	Phase 3
Recruiting	A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination NCT04224493	Epizyme, Inc.	Phase 3
Unknown	A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL) NCT04324879	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Phase 2
Recruiting	Towards Personalized Medicine for Refractory/Relapsed Follicular Lymphoma Patients: the Cantera/Lupiae Registr NCT04587388	European Hematology Association - Lymphoma Group	—
Completed	Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Ce NCT03939026	Allogene Therapeutics	Phase 1